“Very clear, unequivocal and unprecedented” is how Zymeworks CEO Kenneth Galbraith heralded results from a mid-phase study of biliary tract cancer drug zanidatamab, which sent shares soaring nearly 30%.

Someday in the future, migraine relief could be just a click away.

Inflammatory bowel disease, or IBD, is tough to treat, and existing therapies don’t work for everyone. Now, researchers have discovered a previously unknown link between a “master regulator” of gut processes and inflammatory molecules involved in IBD—and have a drug that could treat it.

The tricky indication of nonalcoholic steatohepatitis (NASH) has confounded many a biotech, but Madrigal Pharmaceuticals and its investors think the company is finally onto a winner with its second positive phase 3 readout.

Moon Surgical quickly cleared two development stages this month as it blasts toward its goal of providing laparoscopic surgeons with a robotic helper on the operating table.

After decades of jokes (and legitimate complaints) that doctors’ handwriting can be largely inscrutable, Google has decided the easiest way to fix the problem is to train a computer to read those illegible prescription notes for you.

Heading into the new year, Alnylam Pharmaceuticals is bullish that its RNA interference platform will continue to churn out effective and commercially viable medicines.

Breast cancer is the most commonly diagnosed type of cancer globally, according to the World Health Organization, which has estimated that the case count could climb from about 2.3 million new diagnoses in 2020 to more than 3 million in 2040.

Synaptogenix had an admirable goal, but, unfortunately, aspirations don’t directly translate to clinical success, particularly in neurodegenerative diseases.

The heart-focused artificial intelligence company Anumana is looking to break new ground for its algorithms through a partnership with Pfizer. They plan to develop programs that can help diagnose cases of cardiac amyloidosis, where misfolded proteins build up around the tissue.